Journal: European journal of haematology
This publication is a narrative review focused on anemia in patients with cancer and its management.
It emphasizes that even mild-to-moderate anemia is clinically meaningful in oncology, contributing to:
- Fatigue
- Functional decline
- Worse tolerance of systemic therapy
- Poorer overall prognosis
It highlights that correcting anemia and improving hemoglobin can:
- Reduce fatigue
- Improve emotional well-being
- Enhance overall quality of life
The authors summarize the current understanding of the mechanisms of cancer-related anemia, including disease- and treatment-related factors, and then review available therapeutic approaches.
- Therapeutic approaches range from well-established supportive measures to newer, investigational, and targeted strategies.
- The review is structured to move from conventional options to emerging therapies.
- It distinguishes management considerations for patients with solid tumors versus hematologic malignancies.
The overarching goal is to provide a practical framework to help clinicians individualize anemia treatment in cancer care, with a strong focus on:
- Quality-of-life improvement
- Optimization of overall outcomes